Last reviewed · How we verify

NCT03219190

A High School Program for Preventing Prescription Drug Misuse

Completed NA Results posted Last updated 10 March 2026
What this trial tests

NA trial testing LST High School Hybrid in Prescription Drug Abuse in 1,804 participants. Completed in 1 July 2023.

Timeline
1 February 2022
Primary endpoint
1 July 2023
1 July 2023

Quick facts

Lead sponsorNational Health Promotion Associates, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment1,804
Start date1 February 2022
Primary completion1 July 2023
Estimated completion1 July 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

National Health Promotion Associates, Inc. — full company profile →

Who can join

Adults 14 to 18, any sex, with Prescription Drug Abuse or Substance Abuse. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Prescription Drug Misuse (i.e., Prescription Drug Use Without a Doctor's Prescription) Primary · Assessed at pre-test and post-test assessment, post-test assessment approximately 2-4 weeks post-intervention reported

This measure includes prescription drug misuse of sedatives, painkillers, and stimulants. Frequency of sedative, painkiller, and stimulant use without a doctor's prescription; measured on a 9-point scale, including Never (1), A few times but NOT in the past year (2), A few times a year (3), Once a month (4), A few times a month (5), Once a week (6), A few times a week (7), Once a day (8), More than once a day (9); Unabbreviated scale title: Prescription Drug Misuse (i.e., prescription drug use without a doctor's prescription); Minimum value = 1; maximum value = 9; Higher scores are a worse o

Prescription sedative misuse
GroupValue95% CI
LST High School Hybrid1.06± 0.02
Treatment as Usual (Control)1.12± 0.03
Prescription painkiller misuse
GroupValue95% CI
LST High School Hybrid1.11± 0.03
Treatment as Usual (Control)1.13± 0.04
Prescription stimulant misuse
GroupValue95% CI
LST High School Hybrid1.09± 0.02
Treatment as Usual (Control)1.11± 0.04
Perceived Risk of Prescription Drug Misuse Secondary · Assessed at pre-test and post-test assessment, post-test assessment approximately 2-4 weeks post-intervention reported

This measure includes perceived risk of harm associated with using prescription sedatives, painkillers, and stimulants when prescribed for someone else, measured on a 4-point scale from "No Risk" to "Great Risk;" also option for "Can't say, drug unfamiliar"; Unabbreviated scale title: Perceived Risk of Prescription Drug Misuse; Minimum value = 1; maximum value = 4; Higher scores are a better outcome

Prescription sedatives, risk o harm
GroupValue95% CI
LST High School Hybrid2.71± 0.02
Treatment as Usual (Control)2.59± 0.03
Prescription painkillers, risk o harm
GroupValue95% CI
LST High School Hybrid2.75± 0.02
Treatment as Usual (Control)2.58± 0.03
Prescription stimulants, risk o harm
GroupValue95% CI
LST High School Hybrid2.71± 0.02
Treatment as Usual (Control)2.58± 0.03

Sponsor's own description

This project will develop and evaluate a program to prevent prescription drug misuse in high school students

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Retraction of "Preventing tobacco and alcohol use among high school students through a hybrid online and in-class intervention: A randomized controlled trial," by Williams et al. (2025).
    · 2026 · PMID 41627337 · DOI 10.1037/adb0001131
  2. Impact of a Hybrid Prevention Program for High School Students on Prescription Drug Misuse Outcomes.
    Griffin KW, Williams C, Sousa SM, Botvin GJ. · · 2026 · PMID 41595094 · DOI 10.3390/bs16010154

Verify or expand the search:

Other National Health Promotion Associates, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03219190.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing